CA2660962A1 - Nouvelle composition pharmaceutique pour le traitement de la schizophrenie - Google Patents

Nouvelle composition pharmaceutique pour le traitement de la schizophrenie Download PDF

Info

Publication number
CA2660962A1
CA2660962A1 CA2660962A CA2660962A CA2660962A1 CA 2660962 A1 CA2660962 A1 CA 2660962A1 CA 2660962 A CA2660962 A CA 2660962A CA 2660962 A CA2660962 A CA 2660962A CA 2660962 A1 CA2660962 A1 CA 2660962A1
Authority
CA
Canada
Prior art keywords
lower alkyl
substituted
schizophrenia
pharmaceutical composition
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2660962A
Other languages
English (en)
Inventor
Shinji Takahashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority to CA2660962A priority Critical patent/CA2660962A1/fr
Priority to KR1020117025603A priority patent/KR20120004488A/ko
Priority to EP10719652A priority patent/EP2413940A1/fr
Priority to PCT/JP2010/056144 priority patent/WO2010114163A1/fr
Priority to CN2010800150329A priority patent/CN102378630A/zh
Priority to JP2011541012A priority patent/JP2012521963A/ja
Priority to TW099109850A priority patent/TW201035081A/zh
Publication of CA2660962A1 publication Critical patent/CA2660962A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2660962A 2009-03-31 2009-03-31 Nouvelle composition pharmaceutique pour le traitement de la schizophrenie Abandoned CA2660962A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2660962A CA2660962A1 (fr) 2009-03-31 2009-03-31 Nouvelle composition pharmaceutique pour le traitement de la schizophrenie
KR1020117025603A KR20120004488A (ko) 2009-03-31 2010-03-30 정신분열증의 치료를 위한 2,4,6-트리아미노-1,3,5-트리아진 유도체를 포함하는 조성물
EP10719652A EP2413940A1 (fr) 2009-03-31 2010-03-30 Compositions comprenant des derives de 2, 4, 6-triamino-1, 3, 5-triazine pour le traitement de la schizophrenie
PCT/JP2010/056144 WO2010114163A1 (fr) 2009-03-31 2010-03-30 Compositions comprenant des derives de 2, 4, 6-triamino-1, 3, 5-triazine pour le traitement de la schizophrenie
CN2010800150329A CN102378630A (zh) 2009-03-31 2010-03-30 用于治疗精神分裂症的包含2,4,6-三氨基-1,3,5-三嗪衍生物的组合物
JP2011541012A JP2012521963A (ja) 2009-03-31 2010-03-30 新規統合失調症治療用医薬組成物
TW099109850A TW201035081A (en) 2009-03-31 2010-03-31 Novel pharmaceutical composition for treatment of schizophrenia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2660962A CA2660962A1 (fr) 2009-03-31 2009-03-31 Nouvelle composition pharmaceutique pour le traitement de la schizophrenie

Publications (1)

Publication Number Publication Date
CA2660962A1 true CA2660962A1 (fr) 2010-09-30

Family

ID=42269730

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2660962A Abandoned CA2660962A1 (fr) 2009-03-31 2009-03-31 Nouvelle composition pharmaceutique pour le traitement de la schizophrenie

Country Status (7)

Country Link
EP (1) EP2413940A1 (fr)
JP (1) JP2012521963A (fr)
KR (1) KR20120004488A (fr)
CN (1) CN102378630A (fr)
CA (1) CA2660962A1 (fr)
TW (1) TW201035081A (fr)
WO (1) WO2010114163A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103351348A (zh) * 2013-07-15 2013-10-16 黄河三角洲京博化工研究院有限公司 一种2-甲胺基嘧啶盐酸盐的合成方法
KR200492485Y1 (ko) 2016-02-16 2020-10-23 주식회사 마르시끄 일회용 마스카라

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1982799A (en) 1998-01-23 1999-08-09 Yamanouchi Pharmaceutical Co., Ltd. Novel potassium channel protein
KR100947185B1 (ko) 2000-12-21 2010-03-15 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 조성물
US7375222B2 (en) * 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
JP2010524434A (ja) * 2007-03-26 2010-07-22 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ Kcnh2の統合失調症関連アイソフォームおよび抗精神病薬の開発

Also Published As

Publication number Publication date
WO2010114163A1 (fr) 2010-10-07
TW201035081A (en) 2010-10-01
JP2012521963A (ja) 2012-09-20
CN102378630A (zh) 2012-03-14
KR20120004488A (ko) 2012-01-12
EP2413940A1 (fr) 2012-02-08

Similar Documents

Publication Publication Date Title
EP1727551B1 (fr) Composition pharmaceutique comprenant un derive de benzodiazepine et un inhibiteur de la proteine de fusion du virus respiratoire syncytial
EP1921077B1 (fr) Agent de traitement et/ou de prevention des troubles du sommeil
CA3112129A1 (fr) Polytherapies
CN104302295B (zh) 用tor 激酶抑制剂治疗癌症
TW200413374A (en) Novel adenine derivative and its use
EP3077391B1 (fr) Utilisation de dérivés de benzimidazole-proline
EP3570940B1 (fr) Pridopidine pour utilisation pour traiter le syndrome de l'x fragile
CN111788182B (zh) 毒蕈碱性乙酰胆碱受体m4的拮抗剂
EP2796450B1 (fr) Dérivés 6-aminopyridine-3-ol ou leurs sels pharmaceutiquement acceptables, et composition pharmaceutique contenant ces dérivés ou ces sels comme principes actifs pour la prévention ou le traitement des maladies provoquées par l'angiogenèse
US9540332B2 (en) Benzimidazole derivatives as selective blockers of persistent sodium current
CA3002489A1 (fr) Derives d'indoline-2-one
CA2660962A1 (fr) Nouvelle composition pharmaceutique pour le traitement de la schizophrenie
US20100256152A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
CN107438435A (zh) 抗‑hcmv组合物和方法
US20130172342A1 (en) Benzimidazole derivatives as selective blockers of persistent sodium current
US20120088772A1 (en) Novel pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder
CN113754580B (zh) 一种吡啶吗啉类化合物、其制备方法及其应用
AU2009201338A1 (en) Novel pharmaceutical composition for treatment of schizophrenia
BRPI0901286A2 (pt) nova composição farmacêutica para o tratamento da esquizofrenia
CA3101143A1 (fr) Forme de sel
CN112912078B (zh) 用于治疗雌激素受体阳性乳腺癌的组合疗法
CA2660954A1 (fr) Nouveau sel de derive de 1,3,5-triazine-2,4,6-triamine

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150331